《大行報告》野村上調威高股份(01066.HK)目標價至13.33元 評級「買入」
野村發表研究報告指,威高股份(01066.HK)旗下山東威高骨科材料(688161.SH)日前公布第三季銷售按年下跌39.4%,歸屬股東純利按年跌64.6%,
公司管理層將下跌歸咎於帶量採購政策下去庫存及分銷商銷售模式調整,即從直接銷售模式轉變為寄售模式,影響期內銷售額,撇除相關影響預料期內收入應按年增長25%。
該行指,骨科相關業務佔公司總收入的約14%,相應地將威高今年收入及預測下調3% ,認為市場可能在短期內對消息作出負面反應,但仍看好脊柱固定器械等產品的帶量採購,維持對威高股份「買入」評級,目標價從12.64元上調至13.33元。(gc/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.